ALSO NOTED: Novacea, KuDOS sign deal; Mader leaves CEO spot at Ambrilla; and much more...

> Novacea has signed a deal with KuDOS Pharmaceuticals (a subsidiary of AstraZeneca) for KuDOS' anti-cancer agent AQ4N, Novacea gains the rights to worldwide development and commercialization of AQ4N., which is currently in Phase I clinical trials. Release

> Chutes & Ladders: Hans J. Mader is leaving his position as President and CEO and as a member of the Board at Ambrilia Biopharma. Release

> In a new study, U.S. researchers say they have developed a plant that makes a protein that can be used to manufacture a safe and effective smallpox vaccine. Report

> A scientific team at Taiwan's Vaccine Research and Development Centre spent 13 months and $1.2 million to develop a new, cell-based vaccine to target avian flu. Report

And Finally... Bill and Melinda Gates will receive honorary doctor of medicine degrees for their contributions to global health through the Bill & Melinda Gates Foundation. Release